NCT06625840View on ClinicalTrials.gov

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 18, 2023

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions
Healthy
Interventions
DRUG

MK-1167

Oral Administration

DRUG

Placebo

Oral Administration

Trial Locations (1)

91206

California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International (Site 0001), Glendale

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06625840 - A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) | Biotech Hunter | Biotech Hunter